• Apellis Pharmaceuticals, Inc. announced that Mikael Dolsten, M.D., Ph.D., former Pfizer chief scientific officer, joined its board of directors on March 1, 2026, adding decades of pharmaceutical R&D leadership to the company.
• Dolsten’s track record overseeing the regulatory approval of more than 36 medicines and vaccines may influence how investors assess Apellis’s ability to advance and commercialize its pipeline.
• Next, we’ll examine how Dolsten’s board appointment could interact with Apellis’s existing growth plans in eye and rare kidney diseases.

This technology could replace computers: discover 22 stocks that are working to make quantum computing a reality.

Apellis Pharmaceuticals Investment Narrative Recap

To own Apellis, you need to believe that SYFOVRE and EMPAVELI can sustain meaningful demand in eye and rare kidney diseases while the company manages reimbursement and competition risk. Dolsten’s appointment looks supportive for execution on complex R&D and regulatory paths, but it does not fundamentally change the near term dependence on SYFOVRE uptake or the key risk around pricing pressure and patient access programs.

The most relevant recent development alongside Dolsten’s arrival is Apellis’s full year 2025 earnings, with revenue of US$1,003.78 million and net income of US$22.39 million. This underscores that Apellis has only recently moved into profitability while still carrying a high valuation, so any slowdown in core products or setbacks in pipeline expansion could quickly affect how sustainable that profitability appears.

Yet, against this improving profit picture, investors should be aware that pricing pressure and reimbursement trends could...

Apellis Pharmaceuticals' narrative projects $1.2 billion revenue and $130.6 million earnings by 2028. This requires 16.9% yearly revenue growth and a $358.8 million earnings increase from $-228.2 million today.

Uncover how Apellis Pharmaceuticals' forecasts yield a $33.95 fair value, a 69% upside to its current price.

Exploring Other Perspectives

The most optimistic analysts were modeling revenue of about US$1.4 billion and earnings of roughly US$617 million by 2028, so Dolsten’s arrival could either reinforce that bullish view or prompt you to reconsider how concentrated Apellis still is around SYFOVRE and EMPAVELI.

Explore 3 other fair value estimates on Apellis Pharmaceuticals - why the stock might be worth over 5x more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Apellis Pharmaceuticals research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Apellis Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Apellis Pharmaceuticals' overall financial health at a glance.

Interested In Other Possibilities?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Find 49 companies with promising cash flow potential yet trading below their fair value.
• Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.